AUGX — Augmedix Income Statement
0.000.00%
Last trade - 00:00- $115.66m
- $107.98m
- $44.86m
- 45
- 19
- 20
- 18
Annual income statement for Augmedix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 14.1 | 16.5 | 22.2 | 30.9 | 44.9 |
| Cost of Revenue | |||||
| Gross Profit | 4.68 | 6.79 | 10 | 14 | 21.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 30.9 | 30.2 | 37.8 | 54.4 | 63.6 |
| Operating Profit | -16.7 | -13.7 | -15.6 | -23.5 | -18.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -18.5 | -15.6 | -17.4 | -24.3 | -19 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -18.5 | -15.6 | -17.5 | -24.4 | -19.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -18.5 | -15.6 | -17.5 | -24.4 | -19.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -18.5 | -15.6 | -17.5 | -24.4 | -19.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.689 | -0.581 | -0.647 | -0.634 | -0.436 |
| Dividends per Share |